Abstract
BackgroundRenal cell carcinoma (RCC) is a cancer of increasing incidence and mortality. Currently, there are no immunohistochemical prognostic markers for RCCs in routine use. The aim of this study was to examine for the first time the immunostaining of myosin VI in RCCs as well as its association with E-cadherin and beta-catenin immunostaining and the prognostic significance of these markers in RCCs.MethodsOur study population consisted of 152 patients who underwent surgery for RCCs between 1990 and 1999. The tumours were examined with three immunohistochemical markers: myosin VI, E-cadherin and beta-catenin.ResultsThe immunostaining for cytoplasmic myosin VI was common (72%). One-third of the tumours were immunopositive for nuclear myosin VI. Cytoplasmic myosin VI immunopositivity and nuclear beta-catenin immunostaining were associated with lower Fuhrman grades (p = 0.04 and p = 0.005, respectively), but not stages. There was no significant association between myosin VI immunostaining and the histological subtype of RCC. Nuclear myosin VI was associated with the nuclear expression of beta-catenin. A direct association could also be proven between membranous E-cadherin and cytoplasmic beta-catenin. Cytoplasmic myosin VI immunostaining was a marker of poorer prognosis in multivariate Cox regression model adjusted with stage and Fuhrman grade with hazard ratio 2.4 (95% confidence interval 1.1 to 5.0 with p = 0.024).ConclusionsCytoplasmic myosin VI immunopositivity and nuclear beta-catenin immunostaining were associated with lower Fuhrman grades, and there was a strong positive relationship between E-cadherin immunostaining and beta-catenin immunostaining in RCCs. Cytoplasmic myosin VI immunostaining was associated with poorer prognosis in RCCs.
Highlights
Renal cell carcinoma (RCC) is a cancer of increasing incidence and mortality
The distribution of tumour classes (TNM classification), clinical stages, tumour grades and the histological subtype of the RCC in comparison to the immunostaining pattern for myosin VI, beta-catenin and E-cadherin are described in Table 1, Table 2 and Table 3, respectively
Cytoplasmic myosin VI immunopositivity was associated with lower Fuhrman grades (p = 0.04) but not stages (Table 1)
Summary
Renal cell carcinoma (RCC) is a cancer of increasing incidence and mortality. The aim of this study was to examine for the first time the immunostaining of myosin VI in RCCs as well as its association with E-cadherin and beta-catenin immunostaining and the prognostic significance of these markers in RCCs. Renal cell carcinoma (RCC) is a cancer of increasing incidence and mortality [1]. E-cadherin, a member of the adhesion molecule family of cadherins, mediates predominantly cell-cell adhesion in epithelium and epithelial tumours. It is a tumour suppressor, the loss of which is known to worsen the prognosis of many cancers. Beta-catenin, a member of the catenin family, participates in signal transduction [16,17]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
